Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00355082 · ClinicalTrials.gov registry record · Phase 3
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
A Phase 3 study of Epilepsy, Partial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 226
- Enrollment target
- 20
- Study locations
NCT00355082: Completed Phase 3 study of Epilepsy, Partial, sponsored by GlaxoSmithKline.
NCT00355082 is a Phase 3 study of Epilepsy, Partial that has completed, run by GlaxoSmithKline. The registered enrollment target is 226 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00355082, a Phase 3 study of Epilepsy, Partial, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 226 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
Primary Outcome
The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who reached Visit 5 minus major protocol violators. The Control group is composed of data from other similar studies and is not part of this study.
Conditions Studied
Interventions
- DRUG lamotrigine, 300 mg/day
- DRUG lamotrigine, 250 mg/day
Study Locations (20)
Arizona
- GSK Investigational Site - Litchfield Park
- GSK Investigational Site - Mesa
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Tucson
- GSK Investigational Site - Tucson
California
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Pasadena
- GSK Investigational Site - Santa Ana
- GSK Investigational Site - Santa Monica
Florida
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Loxahatchee Groves
- GSK Investigational Site - Sunrise
- GSK Investigational Site - Tampa
Connecticut
- GSK Investigational Site - Danbury
- GSK Investigational Site - Fairfield
Alabama
- GSK Investigational Site - Alabaster
Arkansas
- GSK Investigational Site - Fayetteville
Delaware
- GSK Investigational Site - Newark
Georgia
- GSK Investigational Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
What the finished NCT00355082 record still lists
NCT00355082 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Epilepsy, Partial appearing as the primary indexed condition, and to 2 interventions - of which lamotrigine, 300 mg/day is the first listed.
NCT00355082 names 20 study sites across 8 states, led by Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00355082 about?
NCT00355082 is a clinical study titled "Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy". This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
What is the current status of trial NCT00355082?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 226 participants. The study started on 2006-05. Estimated completion is 2008-11.
What conditions does trial NCT00355082 study?
This clinical trial studies the following conditions: Epilepsy, Partial.
What interventions are being tested in trial NCT00355082?
The interventions under investigation include: lamotrigine, 300 mg/day (DRUG), lamotrigine, 250 mg/day (DRUG).
Who is sponsoring clinical trial NCT00355082?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00355082 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Partial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00355082's enrollment target sits among peer trials
226 1310th of 2000 higher than 690 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia